Nonprescription Nasonex Gains UK Regulator’s Support
This article was originally published in The Pink Sheet
Executive Summary
The UK MHRA is accepting comments on its recommendation to allow pharmacy sales of nonprescription Nasonex Allergy Control (mometasone furoate/100 mcg).
You may also be interested in...
Bayer Consumer Health Journey Still Short Of Destination
Bayer says issues encountered after acquiring Merck & Co.’s consumer brands two years ago have meant slower growth than expected. But it suggests that’s not a precedent for its planned mega-merger with Monsanto.
Deals Shaping the Medical Industry, October 2016
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2016.
Bayer's ClariSpray Brings Hint Of Familiar Brand To Nasal Allergy Space
ClariSpray is the same formulation as GSK Consumer Healthcare's Flonase Allergy Relief, but Bayer is not making all of the same claims because OTC Flonase for another year has exclusivity among OTC intranasal corticosteroids for eye-related allergy relief.